Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Change in Account Payables (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Change in Account Payables for 15 consecutive years, with $34000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 63.04% year-over-year to $34000.0, compared with a TTM value of $386000.0 through Sep 2025, up 145.95%, and an annual FY2024 reading of -$100000.0, up 87.06% over the prior year.
  • Change in Account Payables was $34000.0 for Q3 2025 at Alaunos Therapeutics, up from -$22000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.7 million in Q1 2021 and bottomed at -$2.6 million in Q2 2021.
  • Average Change in Account Payables over 5 years is -$15631.6, with a median of -$22000.0 recorded in 2025.
  • The sharpest move saw Change in Account Payables plummeted 483.67% in 2021, then soared 1757.89% in 2025.
  • Year by year, Change in Account Payables stood at -$229000.0 in 2021, then crashed by 179.91% to -$641000.0 in 2022, then dropped by 6.24% to -$681000.0 in 2023, then soared by 108.66% to $59000.0 in 2024, then crashed by 42.37% to $34000.0 in 2025.
  • Business Quant data shows Change in Account Payables for TCRT at $34000.0 in Q3 2025, -$22000.0 in Q2 2025, and $315000.0 in Q1 2025.